Epigenetically driven and early immune evasion in colorectal cancer evolution - Nature Genetics

This study nominates immune escape as an early event in colorectal cancer and shows how this can be driven through both genetic and epigenetic changes.

nature.com

Somatic mutation and selection at population scale - Nature

A new version of nanorate DNA sequencing, with an error rate lower than five errors per billion base pairs and compatible with whole-exome and targeted capture, enables epidemiological-scale studies of somatic mutation and selection and the generation of high-resolution selection maps across coding and non-coding sites for many genes.

nature.com

DNA mutagenesis driven by transcription factor competition with mismatch repair

Competition between transcription factors and mismatch repair machinery drives localized hypermutation at regulatory elements, with implications for cancer and genome evolution.

cell.com

Fluctuating DNA methylation tracks cancer evolution at clinical scale - Nature

Cancer evolutionary dynamics are quantitatively inferred using a method, EVOFLUx, applied to fluctuating DNA methylation.

nature.com

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer - Nature

A single-cell sequencing study using more than 30,000 tumour genomes from human ovarian cancers shows that whole-genome doubling is an ongoing mutational process that drives tumour evolution and disru...

nature.com

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics

The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.

nature.com

InSIGHT 2026

REGISTRATION NOW OPEN Register NowCall for Abstracts Now Open! Submit Your AbstractWelcome MessageWelcome to Singapore, Selamat Datang, 欢迎, வருக வருக. On behalf of InSIGHT, we are delighted to invite....

insight2026.org

Changes to the 2026 and 2027 Work Programmes

With the launch of the competitions for grants under ERC Work Programme 2026 in July of this year, several changes to the submission of applications and the evaluation of proposals will apply. The mai...

europa.eu

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

biorxiv.org

Abstract 6427: Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers

Abstract. Cancer interception represents a new approach, aimed at targeting precancerous lesions and therefore preventing cancer occurrence. Lynch syndrome (LS) is one of the most prevalent hereditary...

aacrjournals.org

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

biorxiv.org

Senior scientist – functional genomics

Senior scientist – functional genomics Location: Cambridge Salary: Competitive About AstraZeneca AstraZeneca is a global, science-led, and patient-focused biopharmaceutical company that focuses on the...

astrazeneca.wd3.myworkdayjobs.com

Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance - BJC Reports

BJC Reports - Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance

nature.com

Tahoe-100M: A Giga-Scale Single-Cell Perturbation Atlas for Context-Dependent Gene Function and Cellular Modeling

Building predictive models of the cell requires systematically mapping how perturbations reshape each cell's state, function, and behavior. Here, we present Tahoe-100M, a giga-scale single-cell atlas of 100 million transcriptomic profiles measuring how each of 1,100 small-molecule perturbations impact cells across 50 cancer cell lines. Our high-throughput Mosaic platform, composed of a highly diverse and optimally balanced 'cell village', reduces batch effects and enables parallel profiling of thousands of conditions at single-cell resolution at an unprecedented scale. As the largest single-cell dataset to date, Tahoe-100M enables artificial-intelligence (AI)-driven models to learn context-dependent functions, capturing fundamental principles of gene regulation and network dynamics. Although we leverage cancer models and pharmacological compounds to create this resource, Tahoe-100M is fundamentally designed as a broadly applicable perturbation atlas and supports deeper insights into cell biology across multiple tissues and contexts. By publicly releasing this atlas, we aim to accelerate the creation and development of robust AI frameworks for systems biology, ultimately improving our ability to predict and manipulate cellular behaviors across a wide range of applications. ### Competing Interest Statement Jesse Zhang, Airol A Ubas, Richard de Borja, Valentine Svensson, Nicole Thomas, Neha Thakar, Ian Lai, Aidan Winters, Umair Khan, Matthew G. Jones, Daniele Merico, Nima Alidoust, Hani Goodarzi, Johnny Yu, have received compensation and/or equity from Vevo Therapeutics. Vuong Tran, Joseph Pangallo, Efthymia Papalexi, Ajay Sapre, Hoai Nguyen, Oliver Sanderson, Maria Nigos, Olivia Kaplan, Sarah Schroeder, Bryan Hariadi, Simone Marrujo, Crina Curca Alec Salvino, Guillermo Gallareta Olivares, Ryan Koehler, Gary Geiss, Alexander Rosenberg, Charles Roco, have received compensation and/or equity from Parse Biosciences.

bit.ly